{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:26:47Z","timestamp":1793748407406,"version":"4.6.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"45","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100003135","name":"Minnesota Ovarian Cancer Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003135","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,11,25]]},"DOI":"10.1038\/s41388-026-04001-6","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:31:49Z","timestamp":1790875909000},"page":"4861-4874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nuclear cathepsin L induces DNA damage by regulating DNA repair factors in ovarian cancer"],"prefix":"10.1038","volume":"45","author":[{"given":"Prabhu","family":"Thirusangu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upasana","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Pathoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7939-6882","authenticated-orcid":false,"given":"Julie","family":"Staub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2539-9807","authenticated-orcid":false,"given":"Ann L.","family":"Oberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamison L.","family":"VanBlaricom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8825-2178","authenticated-orcid":false,"given":"Nagarajan","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7130-7259","authenticated-orcid":false,"given":"John","family":"Weroha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie N.","family":"Bakkum-Gamez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7232-0802","authenticated-orcid":false,"given":"Viji","family":"Shridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"4001_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s44294-024-00010-6","volume":"2","author":"K Kleinmanns","year":"2024","unstructured":"Kleinmanns K, Bj\u00f8rge L. Enhancing precision oncology in high-grade serous carcinoma: the emerging role of antibody-based therapies. npj Womens Health. 2024;2:7.","journal-title":"npj Womens Health"},{"key":"4001_CR2","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.18.02238","volume":"37","author":"JM Del Campo","year":"2019","unstructured":"Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial. J Clin Oncol. 2019;37:2968\u201373.","journal-title":"J Clin Oncol"},{"key":"4001_CR3","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274\u201384.","journal-title":"Lancet Oncol"},{"key":"4001_CR4","doi-asserted-by":"crossref","unstructured":"Kim D, Nam HJ. PARP inhibitors: clinical limitations and recent attempts to overcome them. Int J Mol Sci. 2022;23:8412.","DOI":"10.3390\/ijms23158412"},{"key":"4001_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.semcancer.2019.09.021","volume":"68","author":"DB Oien","year":"2021","unstructured":"Oien DB, Pathoulas CL, Ray U, Thirusangu P, Kalogera E, Shridhar V. Repurposing quinacrine for treatment-refractory cancer. Semin Cancer Biol. 2021;68:21\u201330.","journal-title":"Semin Cancer Biol"},{"key":"4001_CR6","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ijc.26158","volume":"130","author":"R Preet","year":"2012","unstructured":"Preet R, Mohapatra P, Mohanty S, Sahu SK, Choudhuri T, Wyatt MD, et al. Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. Int J Cancer. 2012;130:1660\u201370.","journal-title":"Int J Cancer"},{"key":"4001_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ygyno.2017.04.022","volume":"146","author":"E Kalogera","year":"2017","unstructured":"Kalogera E, Roy D, Khurana A, Mondal S, Weaver AL, He X, et al. Quinacrine in endometrial cancer: Repurposing an old antimalarial drug. Gynecologic Oncol. 2017;146:187\u201395.","journal-title":"Gynecologic Oncol"},{"key":"4001_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.32768\/abc.202294439-449","volume":"9","author":"A Samanta","year":"2022","unstructured":"Samanta A, Sarkar A. Fighting new wars with old weapons: repurposing of anti-malarial drug for anticancer therapy: quinacrine role in BC treatment. Arch Breast Cancer. 2022;9:439\u201349.","journal-title":"Arch Breast Cancer"},{"key":"4001_CR9","doi-asserted-by":"crossref","unstructured":"Thirusangu P, Pathoulas CL, Ray U, Xiao Y, Staub J, Jin L et al. Quinacrine-induced autophagy in ovarian cancer triggers cathepsin-L mediated lysosomal\/mitochondrial membrane permeabilization and cell death. Cancers. 2021;13:2004.","DOI":"10.3390\/cancers13092004"},{"key":"4001_CR10","doi-asserted-by":"crossref","unstructured":"Oien DB, Ray U, Pathoulas CL, Jin L, Thirusangu P, Jung D, et al. Quinacrine induces nucleolar stress in treatment-refractory ovarian cancer cell lines. Cancers. 2021;13:4645.","DOI":"10.3390\/cancers13184645"},{"key":"4001_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1107\/S0907444902021479","volume":"59","author":"D Turk","year":"2003","unstructured":"Turk D, Guncar G. Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr D Biol Crystallogr. 2003;59:203\u201313.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"4001_CR12","doi-asserted-by":"crossref","unstructured":"Ding X, Zhang C, Chen H, Ren M, Liu X. Cathepsins trigger cell death and regulate radioresistance in glioblastoma. Cells. 2022;11:4108.","DOI":"10.3390\/cells11244108"},{"key":"4001_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bbapap.2005.05.002","volume":"1751","author":"J Ohnishi","year":"2005","unstructured":"Ohnishi J, Ohnishi E, Shibuya H, Takahashi T. Functions for proteinases in the ovulatory process. Biochim Biophys Acta. 2005;1751:95\u2013109.","journal-title":"Biochim Biophys Acta"},{"key":"4001_CR14","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1172\/JCI42918","volume":"120","author":"J Reiser","year":"2010","unstructured":"Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest. 2010;120:3421\u201331.","journal-title":"J Clin Invest"},{"key":"4001_CR15","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41401-019-0286-9","volume":"40","author":"X Shen","year":"2019","unstructured":"Shen X, Zhao Y-f, Xu S-q, Wang L, Cao H-m, Cao Y, et al. Cathepsin L induced PC-12 cell apoptosis via activation of B-Myb and regulation of cell cycle proteins. Acta Pharmacol Sin. 2019;40:1394\u2013403.","journal-title":"Acta Pharmacol Sin"},{"key":"4001_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.brainres.2011.02.092","volume":"1387","author":"B Xiang","year":"2011","unstructured":"Xiang B, Fei X, Zhuang W, Fang Y, Qin Z, Liang Z. Cathepsin L is involved in 6-hydroxydopamine induced apoptosis of SH-SY5Y neuroblastoma cells. Brain Res. 2011;1387:29\u201338.","journal-title":"Brain Res"},{"key":"4001_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.brainres.2009.12.038","volume":"1318","author":"FG Almaguel","year":"2010","unstructured":"Almaguel FG, Liu JW, Pacheco FJ, De Leon D, Casiano CA, De Leon M. Lipotoxicity-mediated cell dysfunction and death involve lysosomal membrane permeabilization and cathepsin L activity. Brain Res. 2010;1318:133\u201343.","journal-title":"Brain Res"},{"key":"4001_CR18","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1074\/mcp.RA119.001392","volume":"18","author":"T Weiss-Sadan","year":"2019","unstructured":"Weiss-Sadan T, Itzhak G, Kaschani F, Yu Z, Mahameed M, Anaki A, et al. Cathepsin L regulates metabolic networks controlling rapid cell growth and proliferation. Mol Cell Proteom. 2019;18:1330\u201344.","journal-title":"Mol Cell Proteom"},{"key":"4001_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0014-5793(88)80736-1","volume":"231","author":"E Kominami","year":"1988","unstructured":"Kominami E, Tsukahara T, Hara K, Katunuma N. Biosyntheses and processing of lysosomal cysteine proteinases in rat macrophages. FEBS Lett. 1988;231:225\u20138.","journal-title":"FEBS Lett"},{"key":"4001_CR20","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1172\/JCI32022","volume":"117","author":"S Sever","year":"2007","unstructured":"Sever S, Altintas MM, Nankoe SR, M\u00f6ller CC, Ko D, Wei C, et al. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest. 2007;117:2095\u2013104.","journal-title":"J Clin Invest"},{"key":"4001_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1097-2765(04)00209-6","volume":"14","author":"B Goulet","year":"2004","unstructured":"Goulet B, Baruch A, Moon NS, Poirier M, Sansregret LL, Erickson A, et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP\/Cux transcription factor. Mol Cell. 2004;14:207\u201319.","journal-title":"Mol Cell"},{"key":"4001_CR22","doi-asserted-by":"crossref","unstructured":"Rudzi\u0144ska M, Parodi A, Soond SM, Vinarov AZ, Korolev DO, Morozov AO et al. The role of cysteine cathepsins in cancer progression and drug resistance. Int J Mol Sci. 2019;20:3602.","DOI":"10.3390\/ijms20143602"},{"key":"4001_CR23","doi-asserted-by":"crossref","unstructured":"Ziegler AR, Xu B, Anderson BM, Liu L, Luedtke S, Sacharz J, et al. Legumain drives processing of cathepsins and nuclear localisation of cathepsin L. bioRxiv. 2025. https:\/\/www.biorxiv.org\/content\/10.1101\/2025.08.17.670765v1.","DOI":"10.1101\/2025.08.17.670765"},{"key":"4001_CR24","doi-asserted-by":"crossref","unstructured":"Vidak E, Javor\u0161ek U, Vizovi\u0161ek M, Turk B. Cysteine cathepsins and their extracellular roles: shaping the microenvironment. Cells. 2019;8:264.","DOI":"10.3390\/cells8030264"},{"key":"4001_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pharmthera.2015.08.007","volume":"155","author":"DR Sudhan","year":"2015","unstructured":"Sudhan DR, Siemann DW. Cathepsin L targeting in cancer treatment. Pharm Ther. 2015;155:105\u201316.","journal-title":"Pharm Ther"},{"key":"4001_CR26","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1074\/jbc.M308347200","volume":"279","author":"T Cirman","year":"2004","unstructured":"Cirman T, Oresi\u0107 K, Mazovec GD, Turk V, Reed JC, Myers RM, et al. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J Biol Chem. 2004;279:3578\u201387.","journal-title":"J Biol Chem"},{"key":"4001_CR27","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1074\/jbc.M008944200","volume":"276","author":"V Stoka","year":"2001","unstructured":"Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, Snipas SJ, et al. Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem. 2001;276:3149\u201357.","journal-title":"J Biol Chem"},{"key":"4001_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2174\/092986610790225932","volume":"17","author":"P Sansanwal","year":"2010","unstructured":"Sansanwal P, Shukla AA, Das TK, Chauhan SS. Truncated human cathepsin L, encoded by a novel splice variant, exhibits altered subcellular localization and cytotoxicity. Protein Pept Lett. 2010;17:238\u201345.","journal-title":"Protein Pept Lett"},{"key":"4001_CR29","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/emboj.2011.225","volume":"30","author":"I Gonzalez-Suarez","year":"2011","unstructured":"Gonzalez-Suarez I, Redwood AB, Grotsky DA, Neumann MA, Cheng EH, Stewart CL, et al. A new pathway that regulates 53BP1 stability implicates cathepsin L and vitamin D in DNA repair. EMBO J. 2011;30:3383\u201396.","journal-title":"EMBO J"},{"key":"4001_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1083\/jcb.201204053","volume":"200","author":"DA Grotsky","year":"2013","unstructured":"Grotsky DA, Gonzalez-Suarez I, Novell A, Neumann MA, Yaddanapudi SC, Croke M, et al. BRCA1 loss activates cathepsin L\u2013mediated degradation of 53BP1 in breast cancer cells. J Cell Biol. 2013;200:187\u2013202.","journal-title":"J Cell Biol"},{"key":"4001_CR31","doi-asserted-by":"crossref","unstructured":"Thirsangu P, Jin L, Ray U, Zhao A, Wu X, Hou X et al. Role of drug induced nuclear CTSL (nCTSL) in DNA damage response in cancer- therapeutic implications. bioRxiv. 2025. https:\/\/www.biorxiv.org\/content\/10.1101\/2025.01.09.632284v2.","DOI":"10.1158\/1538-7445.OVARIAN25-A050"},{"key":"4001_CR32","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/ijc.28818","volume":"135","author":"X He","year":"2014","unstructured":"He X, Khurana A, Roy D, Kaufmann S, Shridhar V. Loss of HSulf-1 expression enhances tumorigenicity by inhibiting Bim expression in ovarian cancer. Int J Cancer. 2014;135:1783\u20139.","journal-title":"Int J Cancer"},{"key":"4001_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nprot.2006.5","volume":"1","author":"PL Olive","year":"2006","unstructured":"Olive PL, Ban\u00e1th JP. The comet assay: a method to measure DNA damage in individual cells. Nat Protoc. 2006;1:23\u201329.","journal-title":"Nat Protoc"},{"key":"4001_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1916-3","volume":"10","author":"S Sarkar Bhattacharya","year":"2019","unstructured":"Sarkar Bhattacharya S, Thirusangu P, Jin L, Roy D, Jung D, Xiao Y, et al. PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses. Cell Death Dis. 2019;10:725.","journal-title":"Cell Death Dis"},{"key":"4001_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ygyno.2012.06.017","volume":"127","author":"C Korch","year":"2012","unstructured":"Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, et al. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecologic Oncol. 2012;127:241\u20138.","journal-title":"Gynecologic Oncol"},{"key":"4001_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287\u201399.","journal-title":"Int J Womens Health"},{"key":"4001_CR37","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","volume":"397","author":"U Menon","year":"2021","unstructured":"Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397:2182\u201393.","journal-title":"Lancet"},{"key":"4001_CR38","doi-asserted-by":"crossref","unstructured":"Jackson LM, Moldovan G-L. Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment. NAR Cancer. 2022;4:zcac042.","DOI":"10.1093\/narcan\/zcac042"},{"key":"4001_CR39","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2022.33.e44","volume":"33","author":"RE Miller","year":"2022","unstructured":"Miller RE, El-Shakankery KH, Lee JY. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies. J Gynecol Oncol. 2022;33:e44.","journal-title":"J Gynecol Oncol"},{"key":"4001_CR40","doi-asserted-by":"publisher","first-page":"105682","DOI":"10.1016\/j.biocel.2019.105682","volume":"119","author":"D Nayak","year":"2020","unstructured":"Nayak D, Tripathi N, Kathuria D, Siddharth S, Nayak A, Bharatam PV, et al. Quinacrine and curcumin synergistically increased the breast cancer stem cells death by inhibiting ABCG2 and modulating DNA damage repair pathway. Int J Biochem Cell Biol. 2020;119:105682.","journal-title":"Int J Biochem Cell Biol"},{"key":"4001_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bcp.2016.01.017","volume":"105","author":"R Preet","year":"2016","unstructured":"Preet R, Siddharth S, Satapathy SR, Das S, Nayak A, Das D, et al. Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. Biochem Pharmacol. 2016;105:23\u201333.","journal-title":"Biochem Pharmacol"},{"key":"4001_CR42","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1158\/1078-0432.CCR-17-1716","volume":"24","author":"S Zhu","year":"2018","unstructured":"Zhu S, Chen Z, Wang L, Peng D, Belkhiri A, Lockhart AC, et al. A combination of SAHA and quinacrine is effective in inducing cancer cell death in upper gastrointestinal cancers. Clin Cancer Res. 2018;24:1905\u201316.","journal-title":"Clin Cancer Res"},{"key":"4001_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cellsig.2018.01.012","volume":"44","author":"Y Fei","year":"2018","unstructured":"Fei Y, Xiong Y, Shen X, Zhao Y, Zhu Y, Wang L, et al. Cathepsin L promotes ionizing radiation-induced U251 glioma cell migration and invasion through regulating the GSK-3\u03b2\/CUX1 pathway. Cell Signal. 2018;44:62\u201371.","journal-title":"Cell Signal"},{"key":"4001_CR44","doi-asserted-by":"publisher","first-page":"19140","DOI":"10.1074\/jbc.M802513200","volume":"283","author":"G Droga-Mazovec","year":"2008","unstructured":"Droga-Mazovec G, Bojic L, Petelin A, Ivanova S, Romih R, Repnik U, et al. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. J Biol Chem. 2008;283:19140\u201350.","journal-title":"J Biol Chem"},{"key":"4001_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/celldisc.2015.19","volume":"1","author":"L Feng","year":"2015","unstructured":"Feng L, Li N, Li Y, Wang J, Gao M, Wang W, et al. Cell cycle-dependent inhibition of 53BP1 signaling by BRCA1. Cell Discov. 2015;1:15019.","journal-title":"Cell Discov"},{"key":"4001_CR46","doi-asserted-by":"crossref","unstructured":"Lei T, Du S, Peng Z, Chen L. Multifaceted regulation and functions of 53BP1 in NHEJ\u2011mediated DSB repair (Review). Int J Mol Med. 2022;50:90.","DOI":"10.3892\/ijmm.2022.5145"},{"key":"4001_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-015-0166-y","volume":"8","author":"X Liu","year":"2015","unstructured":"Liu X, Chong Y, Liu H, Han Y, Niu M. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer. J Ovarian Res. 2015;8:35.","journal-title":"J Ovarian Res"},{"key":"4001_CR48","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/cncr.23354","volume":"112","author":"A Noske","year":"2008","unstructured":"Noske A, Weichert W, Niesporek S, R\u00f6ske A, Buckendahl AC, Koch I, et al. Expression of the nuclear export protein chromosomal region maintenance\/exportin 1\/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 2008;112:1733\u201343.","journal-title":"Cancer"},{"key":"4001_CR49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","volume":"27","author":"HY Fung","year":"2014","unstructured":"Fung HY, Chook YM. Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer Biol. 2014;27:52\u201361.","journal-title":"Semin Cancer Biol"},{"key":"4001_CR50","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","volume":"7","author":"K Parikh","year":"2014","unstructured":"Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)-a novel class of anti-cancer agents. J Hematol Oncol. 2014;7:78.","journal-title":"J Hematol Oncol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-04001-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-04001-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-04001-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:03:22Z","timestamp":1793747002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-04001-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":50,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2026,11,25]]}},"alternative-id":["4001"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-04001-6","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All procedures involving animals were approved in accordance with the ethical standards of the ethics committee of Mayo Clinic Animal Care and Use Committee (IACUC number# A00004236-25, A4514-17). Informed consent was obtained from all participants and clinical samples from patients were obtained at Mayo Clinic (Institutional Review Board (IRB)-approved protocol; 1288-03) and in association with the University of Minnesota Cancer Center Tissue Procurement Facility (IRB approval; 0702E01841).","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}